Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 122

1.

Higher circulating levels of OxLDL % of LDL are associated with subclinical atherosclerosis in female patients with systemic lupus erythematosus.

Ahmad HM, Sarhan EM, Komber U.

Rheumatol Int. 2014 May;34(5):617-23. doi: 10.1007/s00296-013-2875-0.

PMID:
24101173
3.

Anti-ox-LDL antibodies and anti-ox-LDL-B2GPI antibodies in patients with systemic lupus erythematosus.

Nowak B, Szmyrka-Kaczmarek M, Durazińska A, Płaksej R, Borysewicz K, Korman L, Wiland P.

Adv Clin Exp Med. 2012 May-Jun;21(3):331-5.

4.
5.

Apolipoprotein-containing lipoprotein subclasses and subclinical atherosclerosis in systemic lupus erythematosus.

Kiani AN, Fang H, Akhter E, Quiroga C, Simpson N, Alaupovic P, Magder LS, Petri M.

Arthritis Care Res (Hoboken). 2015 Mar;67(3):442-6. doi: 10.1002/acr.22430.

6.

Dysfunctional proinflammatory high-density lipoproteins confer increased risk of atherosclerosis in women with systemic lupus erythematosus.

McMahon M, Grossman J, Skaggs B, Fitzgerald J, Sahakian L, Ragavendra N, Charles-Schoeman C, Watson K, Wong WK, Volkmann E, Chen W, Gorn A, Karpouzas G, Weisman M, Wallace DJ, Hahn BH.

Arthritis Rheum. 2009 Aug;60(8):2428-37. doi: 10.1002/art.24677.

7.

A panel of biomarkers is associated with increased risk of the presence and progression of atherosclerosis in women with systemic lupus erythematosus.

McMahon M, Skaggs BJ, Grossman JM, Sahakian L, Fitzgerald J, Wong WK, Lourenco EV, Ragavendra N, Charles-Schoeman C, Gorn A, Karpouzas GA, Taylor MB, Watson KE, Weisman MH, Wallace DJ, Hahn BH.

Arthritis Rheumatol. 2014 Jan;66(1):130-9. doi: 10.1002/art.38204.

8.

Risk factors for cardiovascular disease in systemic lupus erythematosus.

Svenungsson E, Jensen-Urstad K, Heimbürger M, Silveira A, Hamsten A, de Faire U, Witztum JL, Frostegård J.

Circulation. 2001 Oct 16;104(16):1887-93.

10.

Heterogeneity of peripheral blood monocytes, endothelial dysfunction and subclinical atherosclerosis in patients with systemic lupus erythematosus.

Mikołajczyk TP, Osmenda G, Batko B, Wilk G, Krezelok M, Skiba D, Sliwa T, Pryjma JR, Guzik TJ.

Lupus. 2016 Jan;25(1):18-27. doi: 10.1177/0961203315598014.

PMID:
26251402
11.

Cardiometabolic and immune factors associated with increased common carotid artery intima-media thickness and cardiovascular disease in patients with systemic lupus erythematosus.

Ammirati E, Bozzolo EP, Contri R, Baragetti A, Palini AG, Cianflone D, Banfi M, Uboldi P, Bottoni G, Scotti I, Pirillo A, Grigore L, Garlaschelli K, Monaco C, Catapano AL, Sabbadini MG, Manfredi AA, Norata GD.

Nutr Metab Cardiovasc Dis. 2014 Jul;24(7):751-9. doi: 10.1016/j.numecd.2014.01.006.

PMID:
24787906
12.

Femoral plaques confound the association of circulating oxidized low-density lipoprotein with carotid atherosclerosis in a general population aged 35 to 55 years: the Asklepios Study.

Langlois MR, Rietzschel ER, De Buyzere ML, De Bacquer D, Bekaert S, Blaton V, De Backer GG, Gillebert TC; Asklepios Investigators..

Arterioscler Thromb Vasc Biol. 2008 Aug;28(8):1563-8. doi: 10.1161/ATVBAHA.108.167346.

13.

Decreased circulating endothelial progenitor cells as an early risk factor of subclinical atherosclerosis in systemic lupus erythematosus.

Castejon R, Jimenez-Ortiz C, Valero-Gonzalez S, Rosado S, Mellor S, Yebra-Bango M.

Rheumatology (Oxford). 2014 Apr;53(4):631-8. doi: 10.1093/rheumatology/ket367.

14.

Metabolic syndrome, endothelial injury, and subclinical atherosclerosis in patients with systemic lupus erythematosus.

Mok CC, Poon WL, Lai JP, Wong CK, Chiu SM, Wong CK, Lun SW, Ko GT, Lam CW, Lam CS.

Scand J Rheumatol. 2010;39(1):42-9. doi: 10.3109/03009740903046668.

PMID:
20132070
15.

Oxidized LDL and AGE-LDL in circulating immune complexes strongly predict progression of carotid artery IMT in type 1 diabetes.

Hunt KJ, Baker N, Cleary P, Backlund JY, Lyons T, Jenkins A, Virella G, Lopes-Virella MF; DCCT/EDIC Research Group..

Atherosclerosis. 2013 Dec;231(2):315-22. doi: 10.1016/j.atherosclerosis.2013.09.027.

17.

Proinflammatory high-density lipoprotein as a biomarker for atherosclerosis in patients with systemic lupus erythematosus and rheumatoid arthritis.

McMahon M, Grossman J, FitzGerald J, Dahlin-Lee E, Wallace DJ, Thong BY, Badsha H, Kalunian K, Charles C, Navab M, Fogelman AM, Hahn BH.

Arthritis Rheum. 2006 Aug;54(8):2541-9.

18.

Subclinical peripheral arterial disease in rheumatoid arthritis.

Stamatelopoulos KS, Kitas GD, Papamichael CM, Kyrkou K, Zampeli E, Fragiadaki K, Panoulas VF, Mavrikakis M, Sfikakis PP.

Atherosclerosis. 2010 Sep;212(1):305-9. doi: 10.1016/j.atherosclerosis.2010.05.007.

PMID:
20553683
19.

Disease Activity, Oxidized-LDL Fraction and Anti-Oxidized LDL Antibodies Influence Cardiovascular Risk in Rheumatoid Arthritis.

Nowak B, Madej M, Łuczak A, Małecki R, Wiland P.

Adv Clin Exp Med. 2016 Jan-Feb;25(1):43-50. doi: 10.17219/acem/29847.

20.

Circulating FABP4 is a marker of metabolic and cardiovascular risk in SLE patients.

Parra S, Cabré A, Marimon F, Ferré R, Ribalta J, Gonzàlez M, Heras M, Castro A, Masana L.

Lupus. 2014 Mar;23(3):245-54. doi: 10.1177/0961203313517405.

PMID:
24390652
Items per page

Supplemental Content

Support Center